Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

Recombinant human PH20 hyaluronidase (rHuPH20) is used to facilitate dispersion of subcutaneously delivered fluids and drugs. This report summarizes rHuPH20 immunogenicity findings from clinical trials where rHuPH20 was co-administered with SC human immunoglobulin, trastuzumab, rituximab, or insulin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:AAPS J
Hlavní autoři: Rosengren, Sanna, Dychter, Samuel S., Printz, Marie A., Huang, Lei, Schiff, Richard I., Schwarz, Hans-Peter, McVey, John K., Drake, Fred H., Maneval, Dan C., Kennard, Don A., Frost, Gregory I., Sugarman, Barry J., Muchmore, Douglas B.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2015
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4540732/
https://ncbi.nlm.nih.gov/pubmed/25967925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1208/s12248-015-9782-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky